Terms for a research and licensing collaboration between CRISPR company Intellia Therapeutics (Nasdaq: NTLA) and privately-held cell therapy firm Kyverna Therapeutics have been agreed.
California-based Kyverna is working on a new class of therapies for autoimmune and inflammatory diseases.
The companies will collaborate on an allogeneic CAR T-cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze